ArticleRespirology case reports2025
From Inoperable to Remission: Complete Response in Advanced Thymoma B3 With Immunotherapy-A Case Report.
Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From Inoperable to Remission: Complete Response in Advanced Thymoma B3 With Immunotherapy-A Case Report.Respirology case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymoma is a rare thymic epithelial tumour, often detected incidentally on imaging. We report a 30-year-old female presenting with cough and chest discomfort, whose evaluation revealed a large anterior mediastinal mass compressing the heart and superior vena cava. Histopathology confirmed type B3 thymoma. The patient underwent thymectomy with residual disease, followed by adjuvant radiotherapy and prolonged pembrolizumab immunotherapy. Serial imaging demonstrated marked tumour regression, with residual metabolically inactive tissue on PET scan, consistent with non-viable remnants. This favourable outcome is notable given the incomplete (R2) resection, where prognosis is typically poor. The case illustrates the effectiveness of a multimodal approach incorporating immune checkpoint blockade in advanced thymoma, an area with limited clinical evidence. Reports on pembrolizumab use after incomplete thymectomy remain limited in the global literature, and this case highlights its potential role in extending disease control and improving outcomes in aggressive thymoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.